About Apheris
Our federated computing technology enables global pharma companies to collaborate securely on large AI models that accelerate drug discovery, without ever sharing their proprietary data. By powering multi-partner data networks across small molecules, antibodies, and protein folding, Apheris is redefining how science and AI intersect.
We currently host two flagship networks: the AI Structural Biology (AISB) Network, focused on protein co-folding and binding affinity prediction, and the ADMET Network, focused on small-molecule property prediction. In addition, we have just launched ApherisFold, an enterprise co-folding application that enables pharma teams to deploy cutting-edge models such as OpenFold 3 and Boltz-2 directly within their own environments.
We are scaling rapidly and are now at a stage where professional, well-structured people processes are critical to sustaining execution quality, team health, and culture as we grow.




